fulltext.study @t Gmail

Therapeutic targeting of innate immunity with Toll-like receptor 4 (TLR4) antagonists

Paper ID Volume ID Publish Year Pages File Format Full-Text
14600 1232 2012 10 PDF Available
Title
Therapeutic targeting of innate immunity with Toll-like receptor 4 (TLR4) antagonists
Abstract

Early recognition of invading bacteria by the innate immune system has a crucial function in antibacterial defense by triggering inflammatory responses that prevent the spread of infection and suppress bacterial growth. Toll-like receptor 4 (TLR4), the innate immunity receptor of bacterial endotoxins, plays a pivotal role in the induction of inflammatory responses. TLR4 activation by bacterial lipopolysaccharide (LPS) is achieved by the coordinate and sequential action of three other proteins, LBP, CD14 and MD-2 receptors, that bind lipopolysaccharide (LPS) and present it to TLR4 by forming the activated (TLR4-MD-2-LPS)2 complex. Small molecules active in modulating the TLR4 activation process have great pharmacological interest as vaccine adjuvants, immunotherapeutics or antisepsis and anti-inflammatory agents. In this review we present natural and synthetic molecules active in inhibiting TLR4-mediated LPS signalling in humans and their therapeutic potential. New pharmacological applications of TLR4 antagonists will be also presented related to the recently discovered role of TLR4 in the insurgence and progression of neuropathic pain and sterile inflammations.

Keywords
Toll-like receptor 4 (TLR4); CD14; MD-2; LPS; Inflammation; Innate immunity; Sepsis; Vaccine adjuvant; Immunotherapeutic
First Page Preview
Therapeutic targeting of innate immunity with Toll-like receptor 4 (TLR4) antagonists
Publisher
Database: Elsevier - ScienceDirect
Journal: Biotechnology Advances - Volume 30, Issue 1, January–February 2012, Pages 251–260
Authors
, ,
Subjects
Physical Sciences and Engineering Chemical Engineering Bioengineering